Header Logo

Connection

Elizabeth Evans to Opiate Substitution Treatment

Back to Details
This is a "connection" page, showing publications Elizabeth Evans has written about Opiate Substitution Treatment.
Elizabeth Evans
Connection Strength
5.596
Opiate Substitution Treatment
  1. Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.
    View in: PubMed
    Score: 0.797
  2. Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.
    View in: PubMed
    Score: 0.785
  3. Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2?years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019 11; 106:19-28.
    View in: PubMed
    Score: 0.551
  4. Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015 Jun; 110(6):996-1005.
    View in: PubMed
    Score: 0.406
  5. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
    View in: PubMed
    Score: 0.194
  6. Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Dec; 122:104252.
    View in: PubMed
    Score: 0.185
  7. Bailey A, Senthilkumar R, Evans EA. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail. J Addict Med. 2023 Sep-Oct 01; 17(5):568-573.
    View in: PubMed
    Score: 0.179
  8. Bailey A, Evans EA. Holyoke Early Access to Recovery and Treatment (HEART): A case study of a court-based intervention to reduce opioid overdose. J Ethn Subst Abuse. 2024 Oct-Dec; 23(4):1039-1061.
    View in: PubMed
    Score: 0.175
  9. Harrington C, Bailey A, Delorme E, Hano S, Evans EA. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19. Subst Use Misuse. 2023; 58(2):266-274.
    View in: PubMed
    Score: 0.174
  10. Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Int J Drug Policy. 2022 Dec; 110:103803.
    View in: PubMed
    Score: 0.170
  11. Fiddian-Green A, Gubrium A, Harrington C, Evans EA. Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder. Int J Environ Res Public Health. 2022 07 30; 19(15).
    View in: PubMed
    Score: 0.169
  12. Evans EA. Commentary on Adams et al.: using administrative big data for the public good. Addiction. 2022 10; 117(10):2649-2650.
    View in: PubMed
    Score: 0.169
  13. Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat. 2022 07; 138:108746.
    View in: PubMed
    Score: 0.164
  14. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
    View in: PubMed
    Score: 0.163
  15. Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
    View in: PubMed
    Score: 0.152
  16. Donelan CJ, Hayes E, Potee RA, Schwartz L, Evans EA. COVID-19 and treating incarcerated populations for opioid use disorder. J Subst Abuse Treat. 2021 05; 124:108216.
    View in: PubMed
    Score: 0.151
  17. Krebs E, Enns B, Evans E, Urada D, Anglin MD, Rawson RA, Hser YI, Nosyk B. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. Ann Intern Med. 2018 01 02; 168(1):10-19.
    View in: PubMed
    Score: 0.122
  18. Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. Addiction. 2017 May; 112(5):838-851.
    View in: PubMed
    Score: 0.116
  19. Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr; 111(4):695-705.
    View in: PubMed
    Score: 0.108
  20. Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JS. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clin Infect Dis. 2015 Oct 01; 61(7):1157-65.
    View in: PubMed
    Score: 0.104
  21. Nosyk B, Li L, Evans E, Urada D, Huang D, Wood E, Rawson R, Hser YI. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. Drug Alcohol Depend. 2014 Oct 01; 143:149-57.
    View in: PubMed
    Score: 0.097
  22. Nosyk B, Sun H, Evans E, Marsh DC, Anglin MD, Hser YI, Anis AH. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction. 2012 Sep; 107(9):1621-9.
    View in: PubMed
    Score: 0.083
  23. Hser YI, Li J, Jiang H, Zhang R, Du J, Zhang C, Zhang B, Evans E, Wu F, Chang YJ, Peng C, Huang D, Stitzer ML, Roll J, Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction. 2011 Oct; 106(10):1801-9.
    View in: PubMed
    Score: 0.079
  24. Michener PS, Bianchet E, Fox S, Evans EA, Friedmann PD. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder. Harm Reduct J. 2024 07 22; 21(1):138.
    View in: PubMed
    Score: 0.049
  25. Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024 02 12; 19(1):10.
    View in: PubMed
    Score: 0.047
  26. Klemperer EM, Evans EA, Rawson R. A call to action: Contingency management to improve post-release treatment engagement among people with opioid use disorder who are incarcerated. Prev Med. 2023 Nov; 176:107647.
    View in: PubMed
    Score: 0.045
  27. Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, Friedmann PD. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022 11; 109:103823.
    View in: PubMed
    Score: 0.042
  28. Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022 05 01; 234:109394.
    View in: PubMed
    Score: 0.041
  29. Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021 11 01; 228:108996.
    View in: PubMed
    Score: 0.040
  30. Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.